SCHEMBL4856533

SCHEMBL4856533

CCc1cc(NCC(=O)OC(C)(C)C)ccc1OCC(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HMGCR P04035 1/20 0.38
PPARG P37231 2/20 0.38
PPARD Q03181 2/20 0.38
PPARA Q07869 2/20 0.38
MAPT P10636 2/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
MCL1 Q07820 1/20 0.37
HTT P42858 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549431 0.86 HTT (0.47) ALDH1A1KDM4ELMNAPPARGPPARD
SCHEMBL4852883 0.86 APP (0.45) ALDH1A1KDM4EHPGDMAPK1LMNA
SCHEMBL4853455 0.85 MTNR1A (0.40) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL4851598 0.85 LMNA (0.51) ALDH1A1KDM4EHPGDMAPK1LMNA
SCHEMBL4859373 0.85 FFAR1 (0.46) ALDH1A1MAPT
SCHEMBL4860511 0.84 ALDH1A1 (0.44) ITGB1ITGA4ALDH1A1MAPK1LMNA
SCHEMBL4859367 0.83 PSEN1 (0.42) ITGB1ITGA4ALDH1A1KDM4EHPGD
SCHEMBL1549486 0.81 ITGB1 (0.40) ITGB1ITGA4ALDH1A1KDM4EMAPK1
SCHEMBL4860553 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDMAPK1LMNA
SCHEMBL4861306 0.80 ESR1 (0.49) ALDH1A1KDM4EHPGDMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7345067-B2 Aniline derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2008-03-18 US disclosed
EP-1636198-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-22 EP disclosed
WO-2004111020-A1 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-12-23 WO disclosed
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248951-A1 Aniline derivatives, their manufacture and use as pharmaceuticals PPARA, PPARD, PPARG ITGB1 872/4885ITGA4 908/4885ALDH1A1 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.